| Code | CSB-RA003995MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Crovalimab, targeting the complement component 5 (C5) protein. C5 plays a central role in the complement cascade, a critical component of the innate immune system. Upon activation, C5 is cleaved into C5a, a potent anaphylatoxin that promotes inflammation, and C5b, which initiates formation of the membrane attack complex (MAC) that can cause cell lysis. Dysregulated C5 activation is implicated in various complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and other inflammatory conditions where excessive complement activation contributes to tissue damage.
Crovalimab is a novel C5 inhibitor engineered with recycling technology to enable subcutaneous administration and extended dosing intervals. This biosimilar antibody serves as a valuable research tool for investigating complement-mediated pathologies, studying C5 biology and signaling pathways, and exploring therapeutic mechanisms of complement inhibition. It enables researchers to conduct in vitro and preclinical studies examining complement system function and its role in various disease models.
There are currently no reviews for this product.